Shenyang Xingqi Pharmaceutical Co.,Ltd. (SHE:300573)
China flag China · Delayed Price · Currency is CNY
36.20
+0.49 (1.37%)
Sep 14, 2026, 3:04 PM CST

SHE:300573 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
2,7002,4531,9241,4401,2271,024
Other Revenue
1119.9219.4927.8623.23.6
2,7112,4731,9431,4681,2501,028
Revenue Growth
22.43%27.24%32.42%17.42%21.59%49.26%
Cost of Revenue
494.18477.94424.53340.36270.08229.01
Gross Profit
2,2171,9951,5191,127979.78798.91
Selling, General & Admin
988.8938.52875.78689.8595.39456.54
Research & Development
295.45225.91220.66167.3145.6188.45
Other Operating Expenses
37.1218.9210.687.166.6613.8
Operating Expenses
1,3231,1841,110867.29748.58558.6
Operating Income
893.82810.48408.42259.93231.2240.31
Interest Expense
-2.31-4.44-5.71-1.44-0.94-5.99
Interest & Investment Income
1.722.255.667.919.933.98
Currency Exchange Gain (Loss)
1.66-1.67-0.110.2-0.09-0.13
Other Non Operating Income (Expenses)
10.08-1.49-2.11-1.15-19.31-1.05
EBT Excluding Unusual Items
904.97805.14406.15265.45220.79237.12
Gain (Loss) on Sale of Investments
5.13--0.02---
Gain (Loss) on Sale of Assets
-0.010.05-0.98-0.040.425.16
Asset Writedown
-3.74-3.7-14.05--0-0
Other Unusual Items
-8.48-1.223.94-0.4212.511.26
Pretax Income
897.87800.28395.03264.99233.72243.54
Income Tax Expense
106.43104.4256.9724.9622.0334.43
Earnings From Continuing Operations
791.43695.86338.06240.04211.68209.11
Minority Interest in Earnings
------14.41
Net Income
791.43695.86338.06240.04211.68194.7
Net Income to Common
791.43695.86338.06240.04211.68194.7
Net Income Growth
57.16%105.84%40.84%13.39%8.72%121.31%
Shares Outstanding (Basic)
358357355353350324
Shares Outstanding (Diluted)
358357355353350325
Shares Change
0.66%0.37%0.60%0.95%7.46%-0.31%
EPS (Basic)
2.211.950.950.680.610.60
EPS (Diluted)
2.211.950.950.680.610.60
EPS Growth
56.13%105.08%40.00%12.33%1.17%120.43%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
597.98482.86218.2755.61-12.96211.9
Free Cash Flow Per Share
1.671.350.610.16-0.040.65
Dividend Per Share
0.9901.1720.7391.3020.3770.163
Dividend Growth
1.46%58.67%-43.24%245.33%130.72%160.19%
Gross Margin
81.77%80.67%78.16%76.81%78.39%77.72%
Operating Margin
32.97%32.77%21.02%17.71%18.50%23.38%
Profit Margin
29.19%28.14%17.39%16.36%16.94%18.94%
Free Cash Flow Margin
22.06%19.53%11.23%3.79%-1.04%20.61%
EBITDA
1,007911.51502.42340.3297.23297.55
EBITDA Margin
37.16%36.86%25.85%23.19%23.78%28.95%
D&A For EBITDA
113.61101.049480.3866.0357.24
EBIT
893.82810.48408.42259.93231.2240.31
EBIT Margin
32.97%32.77%21.02%17.71%18.50%23.38%
Effective Tax Rate
11.85%13.05%14.42%9.42%9.43%14.14%
Revenue as Reported
2,7112,4731,9431,4681,2501,028
Advertising Expenses
---13.81135.22